D

Ginkgo Bioworks Holdings, Inc.

DNA NYSE Healthcare · Biological Products, (No Diagnostic Substances) Boston, MA www.ginkgo.bio
$7.88
Mkt Cap 459.0M
Unless the context otherwise requires, all references in this section to the Company, Ginkgo, we, us, or our refer to the business of Ginkgo Bioworks Holdings, Inc. and our subsidiaries. Overview: Our…

Unless the context otherwise requires, all references in this section to the Company, Ginkgo, we, us, or our refer to the business of Ginkgo Bioworks Holdings, Inc. and our subsidiaries. Overview: Our Mission is to Make Biology Easier to Engineer Our mission is to make biology easier to engineer. That has never changed. Every choice we’ve made with respect to our business model, our platform, our people, and our culture is grounded in whether it will advance our mission. Why? Because: 1. Biology is programmable. All living things run on the same DNA code. 2. Biology matters. The ability to engineer biology has had and will have a profound impact on how we develop new medicines and vaccines, grow our food, and manufacture many of the things we use every day. 3. Biology is hard. Today, it is still too difficult and too costly to engineer biology, preventing critical innovations from reaching the market. Ginkgo sells services to government and commercial customers in two business segments: cell engineering , where we provide tools and biological R&D services across a range of industries, and biosecurity , where we provide services to customers who are working to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. An overview of these two business segments is provided below.

/100 Overall
Calculating score…
Running full analysis
📊 Key Metrics
Loading full analysis…
REVENUE TTM
$132.4M
FCF TTM
-$174.8M
Running full 6-factor analysis…